JP2019509041A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509041A5
JP2019509041A5 JP2018545838A JP2018545838A JP2019509041A5 JP 2019509041 A5 JP2019509041 A5 JP 2019509041A5 JP 2018545838 A JP2018545838 A JP 2018545838A JP 2018545838 A JP2018545838 A JP 2018545838A JP 2019509041 A5 JP2019509041 A5 JP 2019509041A5
Authority
JP
Japan
Prior art keywords
era
amino acid
trail
variant
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018545838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509041A (ja
JP7091248B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/020090 external-priority patent/WO2017151707A1/en
Publication of JP2019509041A publication Critical patent/JP2019509041A/ja
Publication of JP2019509041A5 publication Critical patent/JP2019509041A5/ja
Application granted granted Critical
Publication of JP7091248B2 publication Critical patent/JP7091248B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018545838A 2016-03-01 2017-03-01 低減されたl-グルタミナーゼ活性および増強された安定性を有するl-アスパラギナーゼ変異体および融合タンパク質 Active JP7091248B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662301806P 2016-03-01 2016-03-01
US62/301,806 2016-03-01
US201662347376P 2016-06-08 2016-06-08
US62/347,376 2016-06-08
US201762446026P 2017-01-13 2017-01-13
US62/446,026 2017-01-13
PCT/US2017/020090 WO2017151707A1 (en) 2016-03-01 2017-03-01 L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability

Publications (3)

Publication Number Publication Date
JP2019509041A JP2019509041A (ja) 2019-04-04
JP2019509041A5 true JP2019509041A5 (enExample) 2020-03-26
JP7091248B2 JP7091248B2 (ja) 2022-06-27

Family

ID=58314525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545838A Active JP7091248B2 (ja) 2016-03-01 2017-03-01 低減されたl-グルタミナーゼ活性および増強された安定性を有するl-アスパラギナーゼ変異体および融合タンパク質

Country Status (6)

Country Link
US (1) US10821160B2 (enExample)
EP (1) EP3423480A1 (enExample)
JP (1) JP7091248B2 (enExample)
CN (1) CN109153711B (enExample)
CA (1) CA3054286A1 (enExample)
WO (1) WO2017151707A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781197B1 (en) * 2018-04-19 2025-09-10 Elanco US Inc. Variant asparaginase polypeptides for medical use
US20220362357A1 (en) 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
KR102269634B1 (ko) * 2019-10-31 2021-06-25 대상 주식회사 ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주
KR102283626B1 (ko) * 2019-10-31 2021-08-02 대상 주식회사 glsB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주 및 이의 제조방법
WO2025026424A1 (en) * 2023-08-02 2025-02-06 The Hong Kong Polytechnic University Bioengineered asparaginase fusion proteins
CN117165564B (zh) * 2023-08-16 2025-01-28 云南师范大学 一种ii型l-天冬酰胺酶及其应用
CN118460485B (zh) * 2024-05-07 2025-06-17 山东凯密斯新材料科技有限公司 一种用于合成l-天冬酰胺的天冬酰胺合成酶a突变体及应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE9002213D0 (sv) 1990-06-21 1990-06-21 Hightech Receptor Ab Albumin binding proteins
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
DE60041564D1 (de) 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
EP1654379A4 (en) 2003-06-26 2007-01-17 Lifesensors Inc METHOD AND COMPOSITIONS FOR IMPROVED PROTEIN EXPRESSION AND CLEANING
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
WO2007103290A2 (en) 2006-03-03 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
FI20070455A0 (fi) 2007-06-08 2007-06-08 Reagena Ltd Oy Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
US8969626B2 (en) 2008-07-21 2015-03-03 Polytherics Limited Reagents and method for conjugating biological molecules
WO2010065950A2 (en) 2008-12-05 2010-06-10 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
US9322008B2 (en) 2010-09-01 2016-04-26 Indian Institute Of Technology Mutants of L-asparaginase
WO2012170640A1 (en) 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy
CA2849705A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
ES2670442T3 (es) 2012-05-25 2018-05-30 Janssen Biotech, Inc. Dominios de unión a albúmina de consenso no naturales
US20160213759A1 (en) 2013-09-10 2016-07-28 Board Of Regents, The University Of Texas System Therapeutic asparaginases
NO2776305T3 (enExample) 2014-04-23 2018-01-27
CN104371993B (zh) 2014-10-22 2016-10-19 江南大学 一种酶活提高的天冬酰胺酶突变体

Similar Documents

Publication Publication Date Title
JP2019509041A5 (enExample)
JP2019536462A5 (enExample)
JP2020530300A5 (enExample)
JP2011508742A5 (enExample)
Rodríguez et al. Design and implementation of a high yield production system for recombinant expression of peptides
IL288541B (en) Vaccine against rsv
JP2015513897A5 (enExample)
AU2010288559A8 (en) New endolysin OBPgpLYS
JP2019526248A5 (enExample)
HRP20240676T1 (hr) Proteini domena skele na bazi fibronektina koji vezuju miostatin
JP2021505201A5 (enExample)
JP2011502479A5 (enExample)
JP2004502460A5 (enExample)
JP2019534884A5 (enExample)
JP6612316B2 (ja) 操作されたキメラpeg化adi及び使用方法
Ferrer-Miralles et al. Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine
JP2017514522A5 (enExample)
JP2011523857A5 (enExample)
JP2017529326A5 (enExample)
JP2020530282A5 (enExample)
JP2014526881A5 (enExample)
NZ769391A (en) Serpin fusion polypeptides and methods of use thereof
ES2552337T3 (es) Procedimientos para la preparación de plasminógeno
JP2016537979A5 (enExample)
JP2016503434A5 (enExample)